- Home
- DATS vs NERV Comparison
DATS vs NERV Comparison
Compare DATS & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- NERV
- Stock Information
- Founded
- DATS 2014
- NERV 2007
- Country
- DATS United States
- NERV United States
- Employees
- DATS N/A
- NERV N/A
- Industry
- DATS Computer Software: Prepackaged Software
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- NERV Health Care
- Exchange
- DATS Nasdaq
- NERV Nasdaq
- Market Cap
- DATS 9.5M
- NERV 10.7M
- IPO Year
- DATS 2021
- NERV 2014
- Fundamental
- Price
- DATS $2.79
- NERV $1.44
- Analyst Decision
- DATS
- NERV Hold
- Analyst Count
- DATS 0
- NERV 1
- Target Price
- DATS N/A
- NERV $5.00
- AVG Volume (30 Days)
- DATS 8.0M
- NERV 15.7K
- Earning Date
- DATS 05-13-2025
- NERV 04-30-2025
- Dividend Yield
- DATS N/A
- NERV N/A
- EPS Growth
- DATS N/A
- NERV N/A
- EPS
- DATS N/A
- NERV 0.19
- Revenue
- DATS $436.00
- NERV N/A
- Revenue This Year
- DATS N/A
- NERV N/A
- Revenue Next Year
- DATS N/A
- NERV N/A
- P/E Ratio
- DATS N/A
- NERV $8.63
- Revenue Growth
- DATS N/A
- NERV N/A
- 52 Week Low
- DATS $1.01
- NERV $1.42
- 52 Week High
- DATS $9.34
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- DATS 51.75
- NERV 33.73
- Support Level
- DATS $2.92
- NERV $1.52
- Resistance Level
- DATS $3.39
- NERV $1.80
- Average True Range (ATR)
- DATS 0.60
- NERV 0.12
- MACD
- DATS 0.05
- NERV -0.02
- Stochastic Oscillator
- DATS 24.78
- NERV 29.14
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts, even after they are sent.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.